Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Angiogenesis, the formation of new blood vessels, is a critical process in glioblastoma (GBM) development and progression.
• Vascular endothelial growth factor (VEGF) plays a key role in promoting GBM angiogenesis.
• Targeting VEGF and its receptors (VEGFRs) with antiangiogenic therapies (AATs) has been explored as a therapeutic strategy for GBM, particularly for recurrent disease.

Purpose of the Study:

• To evaluate the efficacy of antiangiogenic therapies (AATs) in treating glioblastoma (GBM).
• To investigate the role of VEGF and VEGFRs in GBM angiogenesis and therapeutic resistance.
• To analyze the outcomes of clinical trials involving AATs for recurrent GBM.

Main Methods:

• Review of clinical trial data for AATs, including bevacizumab (anti-VEGF antibody) and tyrosine kinase inhibitors (TKIs) targeting VEGFRs.
• Analysis of mechanisms underlying GBM resistance to antiangiogenic treatments.
• Assessment of combination therapies involving AATs with other treatment modalities.

Main Results:

• Clinical trials using AATs, alone or in combination, have yielded mixed results in controlling GBM growth.
• A significant challenge identified is the development of resistance to antiangiogenic treatments in GBM.
• Bevacizumab and VEGFR-targeting TKIs demonstrated limited overall efficacy in overcoming GBM resistance.

Conclusions:

• Antiangiogenic therapies targeting VEGF/VEGFRs are not consistently effective for glioblastoma due to acquired resistance.
• Understanding and overcoming resistance mechanisms is crucial for improving GBM treatment outcomes.
• Further therapeutic strategies are needed to enhance the efficacy of antiangiogenic approaches in recurrent GBM.